The Association’s activities are based on three pillars. The first one is the Availability of Innovative Medicines. The AIFP in particular promotes the fair and timely assessing of the benefits of innovative pharmaceuticals and improving their availability to patients. In doing so, the association actively communicates with professional organizations and their representatives as well as with representatives of public administration authorities, patient organizations, and other stakeholders.
The second pillar is Ethics and Transparency. The Association’s and its members’ activities need to adhere to the Code of Ethics. This document defines binding internal rules of self-regulation, which are in most cases stricter and more specific than the existing Czech legislation. The AIFP also promotes a wider application of these principles also to non-member pharmaceutical companies, improvements in the standards of cooperation with the expert medical public, and better observance of general principles in the Czech pharmaceutical market as well as in the healthcare sector.
The third pillar is Benefits for Society. By this we do not mean benefits for patients only, for whom new medicines are often the only chance of improvement of their health condition. This pillar also includes increasing the society’s awareness and knowledge of medicine in respect of pharmaceutical development and clinical trials conducted. Last but not least, there are benefits for the Czech economy as well. New medicines can namely shorten the duration of hospitalization, reduce the number of required interventions, and make it possible for patients to return to normal life earlier. We believe that the results of our research and development, i.e., innovative drugs, can bring significant cost reductions in the social and pension system, thus improving our country’s competitiveness.
The AIFP is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and intensely cooperates with the International Federation of Pharmaceutical Industries and Associations (IFPMA) and Pharmaceutical Research and Manufacturers of America (PhRMA).